Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... The human skin is the largest organ, yet many ... part. Similar to the liver, or heart, the skin must ... grow. Recent reports from the mankatofreepress.com explained how caring for ... as other life supporting organs. The article suggests several types ... increase the appearance of skin, and fight off acne causing ...
(Date:6/18/2013)... The Pistoia Alliance is ... biomolecular representation standard software toolkit and editor under ... HELM (Hierarchical Editing Language for Macromolecules) enables the ... proteins, nucleotides, antibody drug conjugates) whose size and ... impractical or unusable. HELM solves this problem through ...
(Date:6/18/2013)... 2013 The "Bioinformatics Market By Sector (Molecular ... Tools & Data Analysis Services) & Application (Genomics, Proteomics & ... Market Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... (Nasdaq: DCTH ) today announced that Jonathan Lewis, M.D., ... the Company, effective December 2, 2008. Dr. Lewis advised the ... result of additional commitments to new leadership positions. , ... , Dr. Harold Koplewicz, Chairman of the ...
... Therapeutics S.A.,(Alternext: ALEHT), a drug and diagnostic discovery company, ... by the INPI (National Institute of,Industrial Property) during the ... "Since its inception, ... value of its intellectual property and in particular from ...
... 3 GlaxoSmithKline,(LSE/NYSE: GSK ) announced today that ... the previously announced tender offer to purchase all of,the outstanding ... GNLB ), for $1.30 per share in cash without interest ... It is a condition to the completion of ...
Cached Biology Technology:Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 3GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3
(Date:6/19/2013)... specifically for human consumption qualifies as a gluten-free cereal ... (CD), scientists have confirmed in a study published in ... , Joyce Irene Boye and colleagues point out ... States alone have CD. They develop gastrointestinal and other ... that contain gluten-related proteins. Boye,s team sought to expand ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals ... journal aims to provide a forum for rapid publication ... The journal will be co-edited by six Executive Editors, ...
Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... In a new study suggesting pesticides may be associated ... University of California, Berkeley,s School of Public Health have found ... food crops is related to lower intelligence scores at ... increase in measures of organophosphates detected during a mother,s pregnancy ...
... A pulse oximetry training video produced by Rafael Ortega, ... of anesthesiology at Boston Medical Center (BMC) and professor ... and his colleagues is featured in this week,s ... training video, which is the fifth BMC-produced video to ...
... to air pollution early in life and when a woman ... and may be associated with premenopausal breast cancer later in ... The findings indicated that higher air pollution exposure at birth ... a protein important to the adhesion of cells, a function ...
Cached Biology News:Prenatal pesticide exposure tied to lower IQ in children 2Prenatal pesticide exposure tied to lower IQ in children 3Prenatal pesticide exposure tied to lower IQ in children 4Pulse oximetry training video by BMC anesthesiologist published in NEJM 2Air pollution exposure affects chances of developing premenopausal breast cancer 2
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
... Crystal / Mount is the standard ... is designed especially for the permanent preservation ... sections. It is easy to use and ... is the first aqueous mounting medium that ...
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
Biology Products: